Gene Silencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service (RNAi, CRISPR-Cas9, Antisense Oligonucleotides, Others), By Application (Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Therapeutics Manufacturing, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.91 Billion
CAGR (2026-2031)	7.46%
Fastest Growing Segment	RNAi
Largest Market	North America
Market Size (2031)	USD 4.48 Billion

Market Overview

The Global Gene Silencing Market will grow from USD 2.91 Billion in 2025 to USD 4.48 Billion by 2031 at a 7.46% CAGR. Gene silencing refers to a precise therapeutic modality that selectively downregulates the expression of specific disease-causing genes, primarily utilizing mechanisms such as RNA interference and antisense oligonucleotides. The market is fundamentally driven by the rising prevalence of chronic genetic disorders and oncological conditions, which necessitate targeted molecular interventions, alongside significant technological advancements in lipid nanoparticle delivery systems. According to the 'American Society of Gene & Cell Therapy', in '2025', the industry witnessed the initiation of 38 new clinical trials specifically focused on RNA therapies during the second quarter alone, indicating robust developmental momentum.

Despite this progress, the sector faces a substantial challenge regarding the stability and intracellular delivery of silencing agents. The physiological degradation of RNA molecules in the bloodstream and the difficulty of transporting large macromolecules across cellular membranes without inducing off-target toxicity remain critical hurdles that continue to impede the widespread commercialization and clinical efficacy of these therapies.

Key Market Drivers

Accelerated Regulatory Approvals and Expanding Clinical Pipelines currently stand as a primary engine for the Global Gene Silencing Market, transitioning the sector from experimental phases to tangible commercial realization. As regulatory bodies validate the safety profiles of RNA interference and antisense modalities, the pace of market entry for novel therapies has quickened, directly addressing unmet needs in rare genetic diseases. This momentum was highlighted when, according to Biopharma PEG, in December 2024, the FDA approved Tryngolza, a first-in-class RNA-targeted medicine designed to treat familial chylomicronemia syndrome. The commercial scalability of such approved assets significantly impacts revenue generation, validating the sector's financial viability. For instance, according to Alnylam Pharmaceuticals, in October 2025, the company reported third-quarter net product revenues of $851 million, representing a 103% increase year-over-year, which underscores the robust market demand for effective gene silencing interventions.

Simultaneously, Strategic Partnerships and Collaborations are reshaping market dynamics as major pharmaceutical entities seek to overcome persistent intracellular delivery challenges. By acquiring specialized biotech firms, industry leaders can instantly access proprietary delivery platforms—such as antibody oligonucleotide conjugates—that target tissues beyond the liver, including muscle. This trend of high-value consolidation is exemplified when, according to Novartis, in October 2025, the company entered an agreement to acquire Avidity Biosciences for approximately $12 billion to secure its advanced RNA architecture. These capital-intensive collaborations not only provide the necessary funding to navigate complex clinical trials but also accelerate the development of next-generation modalities, ensuring sustainable long-term market expansion.

Download Free Sample Report

Key Market Challenges

The persistent difficulty regarding the stability and intracellular delivery of silencing agents serves as a critical bottleneck restricting the expansion of the Global Gene Silencing Market. Although RNA therapies hold therapeutic promise, the technical inability to transport large macromolecules across cellular membranes without degradation or toxicity frequently leads to clinical failures. These delivery barriers increase the risk profile of developmental programs, causing significant attrition in late-stage trials and making regulatory approval increasingly difficult to secure. As a result, the timeline for commercialization extends significantly, delaying the entry of potentially curative treatments into the healthcare system.

This high-risk environment directly impacts the financial ecosystem necessary for market growth, as investors exercise greater caution toward early-stage ventures grappling with these unresolved technical hurdles. A contraction in capital availability for foundational research stalls the progression of pipeline candidates into commercially viable treatments. According to the 'American Society of Gene & Cell Therapy', in '2025', 'start-up financings raised only $197 million in the second quarter', reflecting a continued decline in investment volume for the sector. This reduction in essential funding impedes the industry's ability to innovate, thereby hampering the overall trajectory of the market.

Key Market Trends

The Rise of RNA-based Biopesticides and Crop Protection in Agriculture represents a transformative expansion of the market, applying gene silencing principles to sustainable pest management. Unlike broad-spectrum chemicals, these biodegradable solutions utilize double-stranded RNA to selectively silence essential genes in specific agricultural pests, minimizing environmental toxicity and preserving beneficial insects. This commercial breakthrough was highlighted when, according to GreenLight Biosciences, in October 2025, the company received U.S. Environmental Protection Agency registration for Norroa, a novel RNA-based solution specifically designed to target and control Varroa mites in honeybee colonies.

Simultaneously, the Emergence of Epigenetic and Transcriptional Gene Silencing is establishing a new therapeutic paradigm that achieves durable gene repression without altering the underlying DNA sequence. This approach leverages epigenetic editors to modulate chemical markers, such as methylation patterns, effectively turning off disease-associated genes at the transcriptional level while avoiding the safety risks associated with double-strand DNA breaks. The investment community has recognized the potential of this modality; for instance, according to Epigenic Therapeutics, in September 2025, the company completed a $60 million Series B financing round to accelerate the clinical development of its proprietary gene modulation platform.

Segmental Insights

The RNA interference segment is projected to witness the fastest growth within the global gene silencing market due to substantial clinical advancements and increasing regulatory acceptance. This expansion is primarily driven by the enhanced ability of RNAi therapeutics to treat rare and chronic genetic disorders with high target specificity. Major pharmaceutical entities are prioritizing this modality following consecutive product approvals by the US Food and Drug Administration. These regulatory milestones have validated the safety and efficacy of RNA interference mechanisms, thereby accelerating investment in research and development pipelines for future therapeutic applications.

Regional Insights

North America maintains a dominant position in the Global Gene Silencing Market, primarily due to substantial investments in genomic research and a robust biotechnology sector. The United States serves as a major contributor, hosting numerous key industry players focused on developing RNA interference and antisense oligonucleotide therapies. This market leadership is further reinforced by a supportive regulatory environment, where the U.S. Food and Drug Administration facilitates the streamlined approval of novel therapeutics. Consequently, high adoption rates of available medical treatments and continuous research and development activities secure the region’s status as the primary revenue generator globally.

Recent Developments

• In March 2025, Novo Nordisk formed a strategic research collaboration with Gensaic to develop tissue-targeted genetic medicines for cardiometabolic diseases. The partnership, valued at up to $354 million in upfront and milestone payments, focuses on utilizing Gensaic’s AI-driven phage display platform to discover novel protein ligands capable of delivering small interfering RNA (siRNA) payloads to specific tissues beyond the liver. This agreement highlights the growing industry focus on overcoming delivery challenges in the gene silencing sector to treat complex metabolic conditions more effectively.
• In March 2025, Alnylam Pharmaceuticals expanded its gene silencing portfolio following the U.S. Food and Drug Administration's approval of a supplemental New Drug Application for AMVUTTRA. This approval extended the indication of the RNA interference therapeutic to include the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a serious and progressive heart condition. The expansion into the cardiology market represented a major commercial inflection point for the company, allowing its RNAi technology to address a significantly larger patient population and further validating the clinical utility of gene silencing mechanism in treating cardiovascular diseases.
• In December 2024, Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration approved its RNA-targeted medicine, TRYNGOLZA, for the treatment of familial chylomicronemia syndrome. This approval marked a significant milestone in the gene silencing market as the first independent commercial launch for the company. The therapy is an antisense oligonucleotide designed to inhibit the production of apoC-III, a protein that regulates triglyceride metabolism. This regulatory clearance provided a novel treatment option for adult patients with this rare genetic disorder, which is characterized by extremely high triglyceride levels and a risk of acute pancreatitis.
• In November 2024, Arrowhead Pharmaceuticals entered into a major global licensing and collaboration agreement with Sarepta Therapeutics to advance clinical and preclinical programs for rare genetic diseases. Under the terms of the agreement, Arrowhead received an immediate payment of $825 million, consisting of cash and an equity investment, and became eligible for future milestone payments potentially totaling approximately $10 billion. The partnership aims to leverage Arrowhead’s proprietary Targeted RNAi Molecule platform to develop gene silencing treatments for diseases affecting the muscle, central nervous system, and lungs, significantly expanding the application of RNA interference technology into new therapeutic areas.

Key Market Players

• Revvity, Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• GenScript Biotech Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• New England Biolabs, Inc.

By Product & Service	By Application	By Region
RNAi CRISPR-Cas9 Antisense Oligonucleotides Others	Neurology Oncology Infectious Diseases Metabolic Diseases Therapeutics Manufacturing Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Gene Silencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gene Silencing Market, By Product & Service:

• RNAi
• CRISPR-Cas9
• Antisense Oligonucleotides
• Others

• Gene Silencing Market, By Application:

• Neurology
• Oncology
• Infectious Diseases
• Metabolic Diseases
• Therapeutics Manufacturing
• Others

• Gene Silencing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE